[Federal Register Volume 62, Number 224 (Thursday, November 20, 1997)]
[Notices]
[Page 62065]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-30421]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to Section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
National Institute on Drug Abuse (NIDA) Initial Review Group and 
Special Emphasis Panel meetings.

    Purpose/Agenda: To review and evaluate grant applications and 
contract proposals.
    Name of Committee: AIDS Behavioral Research Subcommittee.
    Date: December 2-3, 1997.
    Time: 8:30 a.m.
    Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 
Bethesda, MD 20814.
    Contact Person: Mary C. Custer, Ph.D., Scientific Review 
Administrator, Office of Extramural Program Review, National 
Institute on Drug Abuse, 5600 Fishers Lane, Room 10-22, Telephone 
(301) 443-2620.

    Name of Committee: NIDA Special Emphasis Panel (Contract 
Review--``Quantitative Analysis of and Method Development for 
Cannabinoids, Endogenous Compounds, and Other Drugs of Abuse and 
Related Compounds by Radioimmunoassay or Related Methods'').
    Date: December 19, 1997.
    Time: 10:30 a.m.
    Place: Office of Extramural Program Review, National Institute 
on Drug Abuse, NIH, 5600 Fishers Lane, Room 10-42, Rockville, MD 
20857 (Telephone Conference).
    Contact Person: Mr. Eric Zatman, Contract Review Specialist, 
Office of Extramural Program Review, National Institute on Drug 
Abuse, 5600 Fishers Lane, Room 10-42, Rockville, MD 20857, Telephone 
(301) 443-1644.
    The meetings will be closed in accordance with provisions set 
forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The 
applications and/or proposals and the discussions could reveal 
confidential trade secrets or commercial property such as patentable 
material and personal information concerning individuals associated 
with the applications and/or proposals, the disclosure of which 
would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.277, 
Drug Abuse Scientist Development, Research Scientist Development, 
and Research Scientist Awards; 93.278, Drug Abuse National Research 
Service Awards for Research Training; 93.279, Drug Abuse Research 
Programs, National Institutes of Health)

    Dated: November 13, 1997.
LaVerne Y. Stringfield,
Committee Management Officer, NIH.
[FR Doc. 97-30421 Filed 11-19-97; 8:45 am]
BILLING CODE 4140-01-M